It has been a long wait for MiMedx Group, Inc. (MDXG) investors since the inception of the company's internal investigation almost two years ago. The long awaited release of the company's financials should soon be a reality as dates and promises have been made which the company should be on track to honor. This financial release should catalyze the resurrection of the company and the return to potentially being a high growth biotech company with best-in-class products and an intriguing pipeline of candidates. Here are 10 reasons why MiMedx is a buy today for investors